EVO:NASDAQ
Evotec SE
2,61 US$
arrow_downward
-5,09%(-0,14) 1D
2,66 US$
arrow_upward
+1,92% (+0,050)todayPre-market
Closed: 10 ივნ, 16:00:01 GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EVO...
Open
2,68 US$
High
2,70 US$
Low
2,60 US$
Mkt. cap
925,63 მლნ.
Avg. vol.
48,46 ათ.
Volume
0,00
52-wk high
4,44 US$
52-wk low
2,31 US$
EPS
-0,63 US$
Beta
1,92
Shares outstanding
355,82 მლნ.
No. of employees
5 ათ.
Open
2,68 US$
High
2,70 US$
Low
2,60 US$
Mkt. cap
925,63 მლნ.
Avg. vol.
48,46 ათ.
Volume
0,00
52-wk high
4,44 US$
52-wk low
2,31 US$
EPS
-0,63 US$
Beta
1,92
Shares outstanding
355,82 მლნ.
No. of employees
5 ათ.
Analyst outlook
Analyst Ratings
Based on 3 analysts giving stock ratings to EVO in the past 3 months
Buy
Buy
2
Hold
0
Sell
1
12 month forecast
Based on 3 Wall Street analysts offering 12 month price targets for EVO in the last 3 months.
Highest
Current 2,61 US$
7,00 US$ (+168,20%)
Average
5,50 US$ (+110,73%)
Lowest
4,00 US$ (+53,26%)
News stories
From sources across the web
AD HOC NEWS
·
14 საათის წინ
Evotec SE Stock (DE0005664809): Short Interest Eases While Shares Trade Near Lows
AD HOC NEWS
·
1 დღის წინ
Evotec SE stock (DE0005664809): Trading resumes after delisting move and Nasdaq hearing update
AD HOC NEWS
·
2 დღის წინ
Evotec SE stock (DE0005664809): volatility persists as shares retreat from recent lows
Profile
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
About Evotec SE
AI content may include mistakes. Learn more